We performed immunofluorescent analysis of TIGIT positivity on CD3+ T cells on cohorts of primary RCC tumors and matched adjacent normal kidney samples, matched RCC primary and metastatic tumors, and cohorts from four other tumor types (melanoma, NSCLC, cervical, and head and neck cancer). This evidence concerns the gene TIGIT and renal cell carcinoma.